The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $109.07

Today's change+4.17 +3.98%
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $109.07

Today's change+4.17 +3.98%
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc crosses above 20-day moving average

Alnylam Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$4.17 or 3.98% to (U.S.)$109.07 and crossing above its 20-day moving average. Over the last five days, shares have gained 9.23% and 12.44% year to date. Shares have outperformed the S&P 500 by 56.95% during the last year.

Key company metrics

  • Open(U.S.) $104.59
  • Previous close(U.S.) $104.90
  • High(U.S.) $109.72
  • Low(U.S.) $104.59
  • Bid / Ask-- / --
  • YTD % change+12.44%
  • Volume723,192
  • Average volume (10-day)795,424
  • Average volume (1-month)791,866
  • Average volume (3-month)742,906
  • 52-week range(U.S.) $63.48 to (U.S.) $140.00
  • Beta1.98
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.32
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-302.09%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue9192411
Total other revenue--------
Total revenue9192411
Gross profit--------
Total cost of revenue--------
Total operating expense82717056
Selling / general / administrative15131410
Research & development67585646
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income-73-52-46-45
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-71-51-43-44
Income after tax-72-51-21-44
Income tax, total00-220
Net income-72-51-21-44
Total adjustments to net income--------
Net income before extra. items-72-51-21-44
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-72-51-21-44
Inc. avail. to common incl. extra. items-72-51-21-44
Diluted net income-72-51-21-44
Dilution adjustment0000
Diluted weighted average shares84827776
Diluted EPS excluding extraordinary itemsvalue per share-0.85-0.62-0.28-0.58
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.85-0.62-0.28-0.58